GALAD and BALAD-2 serological models validated in a major global cohort

12/19/2016

Researchers from the United Kingdom, Germany, Japan and Hong Kong, under the lead of Prof. P. Johnson, published data on a global validation of the GALAD model for hepatocellular carcinoma (HCC) risk determination and the BALAD-2 model for prognosis assessment. The biomarkers AFP, AFP-L3 and DCP are key components of both models.

Data on cancer diagnosis and outcomes of 6,834 patients (2,430 with HCC and 4,404 with chronic liver disease) were collected. Additionally, data from 229 patients with other hepatobiliary tract cancers were included. The authors of the study investigated the effects of tumour size and etiology on the performance of the GALAD model as well as its ability to discriminate HCC from other hepatobiliary cancers. The performance of BALAD-2 for prognostication was evaluated in patients with respect to their origin and HCC stages.

Prof. A. Vogel, Clinic of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany, explains in an interview how the GALAD and BALAD-2 models can be used in the surveillance and prognosis of patients with hepatocellular carcinoma (HCC).
To watch this interview, please click here.